The expression of epidermal growth factor (EGF) is increased during liver fibrogenesis, and EGF receptor (EGFR) antagonist could attenuate liver fibrosis. Since EGFR is highly expressed by hepatocytes and cholangiocytes in cirrhotic liver, whether hepatic stellate cells express EGFR in response to EGF still needs exploration. Although EGFR antagonist could attenuate liver fibrosis, many ligands with EGF-like domains, besides EGF, can function through EGFR. Whether specifically blocking EGF could attenuate bile duct ligation (BDL)-induced liver fibrosis has not been revealed. BDL induced biliary infarcts and matrix deposition in mouse liver, and EGFR was expressed and phosphorylated by alpha-smooth muscle actin (alpha SMA)-positive myofibroblasts. LX-2 cells expressed EGFR, and these receptors were phosphorylated in the in vitro culture system. Growth curve and cell cycle analysis revealed that EGF could enhance cell proliferation of LX-2 cells. In addition, administration of EGF antibodies markedly reduced the EGF level in serum and the deposition of extracellular matrix in the liver of BDL mice when compared to IgG administration. Administration of EGF antibodies also reduced the phosphorylation of EGFR and the percentage of Ki-67-positive or PCNA-positive liver myofibroblasts of BDL mice when compared to IgG administration. Therefore, activated hepatic stellate cells express EGFR, thus being responsive to EGF signal, and administration of EGF antibodies could attenuate liver fibrosis by restricting the proliferation of myofibroblasts.